Klotho Neurosciences Inc. (KLTO)
NASDAQ: KLTO
· Real-Time Price · USD
0.72
-0.06 (-8.21%)
At close: Aug 20, 2025, 3:59 PM
0.71
-1.20%
After-hours: Aug 20, 2025, 07:59 PM EDT
-8.21% (1D)
| Bid | 0.68 |
| Market Cap | 37.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.71M |
| EPS (ttm) | -0.46 |
| PE Ratio (ttm) | -1.56 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.75 |
| Volume | 1,458,531 |
| Avg. Volume (20D) | 33,164,079 |
| Open | 0.79 |
| Previous Close | 0.78 |
| Day's Range | 0.71 - 0.79 |
| 52-Week Range | 0.11 - 3.91 |
| Beta | 2.53 |
About KLTO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KLTO
Website n/a
4 weeks ago
+12.5%
Klotho Neurosciences shares are trading higher aft...
Unlock content with
Pro Subscription
1 month ago
+6.57%
Klotho Neurosciences shares are trading higher after the company announced the FDA has awarded orphan drug status for KLTO-202 for novel gene therapy in amyotrophic lateral sclerosis patients.
1 month ago · proactiveinvestors.com
Klotho Neurosciences' ALS therapy awarded FDA Orphan Drug DesignationKlotho Neurosciences (NASDAQ:KLTOW) announced that its novel therapy KLTO-202, also known as s-KL-AAV.myo, for the treatment of Amyotrophic Lateral Sclerosis (ALS) has received Orphan Drug Designation...
